

IMS Health & Quintiles are now



Why Consider Australia for your Clinical Trials

Megan Ford
Senior Director, Biotech Delivery Unit
ANZ

Table of Contents

- + Factors for considering Australia
- + Regulatory Environment
- + Start-Up of Clinical Trials
- + Key Opinion Leaders (KOL), Sites, Investigators
- + Quality of Research
- + IQVIA: one partner for your product life cycle
- + IQVIA's Emerging Biopharma offering

Why Australia?



Friendly regulatory environment



Globally competitive start up timelines



KOL, Site and Investigators who deliver



Reputation of high quality & reliable research and data



R & D Tax Incentive

Research-friendly Regulatory Environment

Therapeutic Goods Act 1989

- Access to Unapproved Therapeutic Goods
 - Clinical Trial Notification (CTN)
 - Clinical Trial Exemption (CTX) Scheme


CTN

- Ethics Committees review & approve for Scientific & Ethical validity
- Electronic notification to the TGA → No time delay

Gateway to USA & EU

- Regulatory Authorities accept Australian data, no need to repeat early phase data not conducted under IND


CTNs 2015-2016



Clinical Trial Start-Up in Australia



Latest of Final protocol or SSV to Earliest SIV



Key Opinion Leaders, Site & Investigator Delivery

Internationally recognised Key Opinion Leaders

Australia has a dynamic, ethnically diverse population with excellent medical and health care facilities

Phase I & II

- Dedicated Phase I Units in each major city
- Specialist Oncology Units
- Well established Clinical Trial Networks

Experience with novel designs, compounds and translational medicine

Highest Standard of Quality Research & Data



Quality Research

World class scientists and researchers; multiple Nobel prizes and internationally recognised leaders

Reputation in science and research supported by multiple publication

Good Clinical Practice (GCP) guidelines compliant and built into Legislation



Proven Track Record

Pharmacological agents

FIM

Biosimilar

Devices

Bridging studies




Data

Data collected in Australia is accepted by a number of international regulators including FDA & EMA

History of successful FDA and other regulatory agencies inspections

IQVIA: One Partner for your Product Lifecycle



The genesis of IQVIA has resulted in a single partner that offers a depth and breadth of expertise within each stage of the lifecycle with solutions empowered by data & technology

IQVIA's Emerging BioPharma Offering

Providing the agility and focus of a small CRO with the leading capabilities, resources and global footprint of a large CRO

SMALL CRO

- Nimble
- Flexible
- Attention
- Priority

LARGE CRO

- Experience
- Technology
- Full Service
- Innovation
- Therapeutic Knowledge
- Global



VALUE PROPOSITION

Improve your probability of success by collaborating with the industry leader in trial and program design and execution, in an operational model designed for the unique needs of emerging biopharma

CORE COMPONENTS



Dedicated Project Leadership



Executive Sponsorship



Global Reach & Partnerships



Tailored Operating Model



Data & Performance Dashboard



Therapeutic Expertise

IQVIA Contacts

If you have any questions about conducting clinical trials in Australia please do not hesitate to contact IQVIA



Megan Ford

Senior Director – Biotech Delivery Unit, ANZ

+61 404 832 231

megan.ford@iqvia.com



Qiao Watkins

Associate Director – Business Development, ANZ

+61 432 855 927

qiao.watkins@iqvia.com

IMS Health & Quintiles are now



Thank you for your time today

